Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin
Authors:
Open Access
- 1 December 2009
- journal article
- Published by Springer Nature in Gastric Cancer
- Vol. 12 (4) , 206-211
Abstract
Although triweekly administration of paclitaxel is approved for gastric cancer in Japan, currently, the drug is often delivered with a weekly schedule because of the equivalent efficacy and lesser toxicity of this dosing schedule as compared with the triweekly administration schedule. Weekly administration of paclitaxel as second-line or first-line chemotherapy for gastric cancer has been reported to yield a response rate of about 20%. Because there has been no report of the efficacy of weekly paclitaxel in the third-line setting, this retrospective study investigated the efficacy and toxicities of weekly paclitaxel used in the third-line setting for the treatment of gastric cancer refractory to all three key drugs, fluorouracil, irinotecan, and cisplatin, used in clinical practice. In 85 patients with advanced or recurrent histologically confirmed gastric adenocarcinoma who had failed to respond to prior chemotherapy regimens containing fluorouracil, irinotecan, and cisplatin, paclitaxel (80 mg/m2) was administered weekly, three times, for 3 weeks out of 4. The median number of courses was 3 (range, 1–38). The overall response rate was 23.2% (19/82) in the patients with measurable lesions, and ascites disappeared in 15 of 48 patients (31.3%). Progression-free survival was 105 days and the median survival time was 201 days from the initiation of paclitaxel administration. Grade 3 or 4 leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 25 (29%), 25 (29%), 37 (44%), and 3 (4%) patients. Other, nonhematological, toxicities were nausea, vomiting, anorexia, sensory neuropathy, fatigue, and febrile neutropenia. Weekly paclitaxel administration shows activity against advanced gastric cancer also in the third-line setting.Keywords
This publication has 24 references indexed in Scilit:
- Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancerSurgery Today, 2008
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840Journal of Clinical Oncology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).2007
- Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancerGastric Cancer, 2006
- Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patientsWorld Journal of Gastroenterology, 2006
- Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2005
- [Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines].2004
- Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?JNCI: Journal of the National Cancer Institute, 2000
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995